ADmit Therapeutics
Sant Feliu de Llobregat, Spain
ADmit Therapeutics, S.L. is a company that has developed the MAP-AD® Test for the early detection of Alzheimer’s dementia and is currently in the commercialization stage. Alzheimer’s Disease (AD) is a devastating process for patients and their families and a threat to public health systems in both developed and emerging countries. It is an unmet medical need. It is estimated that more than 47 million people worldwide are suffering this disease, and that the incidence will increase considerably in the coming years due to the increase in life expectancy (130 million patients in 2050). Currently, there is an infradiagnosis of AD cases (mostly in the mild stage), and it is usually done in the moderate stage and with a delay of 12-24 months after the onset of symptoms. There is no any IVD implemented in clinical practice to predict progression to Alzheimer’s dementia in patients with Mild Cognitive Impairment.
Company Info
- Founded
- 2018
- Website
- admit-therapeutics.com/en/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of ADmit Therapeutics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.